Kv7

KV7 ION CHANNEL MODULATION PLATFORM

The lead asset in our Kv7 platform is BHV-7000. BHV-7000 is a potent, selective activator of Kv7.2/7.3 potassium channels, a clinically validated target to regulate the hyperexcitable state in epilepsy. Increasing evidence also suggests the potential for Kv7.2/7.3 activators to treat neuropsychiatric and pain disorders.

Biohaven is developing BHV-7000 for epilepsy, bipolar disorder and major depressive disorder. Biohaven is also exploring BHV-7000 as a potential treatment for KCNQ2 developmental and epileptic encephalopathy (DEE), a rare, serious, and debilitating disease that manifests in infants and children as early-onset seizures and encephalopathy due to a defect in the function of the Kv7.2 channel caused by pathogenic, loss of function mutations in the KCNQ2 gene. Furthermore, preclinical research is underway to evaluate the potential for Kv7 activation as a treatment for pain disorders.

BHV-7000

BHV-7000 is a potent, selective activator of Kv7.2/7.3 potassium channels, a clinically validated target to regulate the hyperexcitable state in epilepsy.

• Potent in the maximal electroshock seizure test without impact on neurobehavior or motor behavior
• Demonstrated minimal GABA_A receptor activation, potentially providing better tolerability
• Well-tolerated in Phase 1 SAD/MAD study without CNS adverse effects typical of anti-seizure medications
• Phase 1 EEG biomarker study confirmed evidence of target engagement in the CNS